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Induction of wild-type p53 in the ECV-304 bladder carcinoma cell
line by infection with a p53 recombinant adenovirus (Ad5CMV-p53)
resulted in extensive apoptosis and eventual death of nearly all of
the cells. As a strategy to determine the molecular events impor-
tant to p53-mediated apoptosis in these transformed cells, ECV-304
cells were selected for resistance to p53 by repeated infections
with Ad5CMV-p53. We compared the expression of 5,730 genes in
p53-resistant (DECV) and p53-sensitive ECV-304 cells by reverse
transcription–PCR, Northern blotting, and DNA microarray analy-
sis. The expression of 480 genes differed by 2-fold or more
between the two p53-infected cell lines. A number of potential
targets for p53 were identified that play roles in cell cycle regula-
tion, DNA repair, redox control, cell adhesion, apoptosis, and
differentiation. Proline oxidase, a mitochondrial enzyme involved
in the prolineypyrroline-5-carboxylate redox cycle, was up-regu-
lated by p53 in ECV but not in DECV cells. Pyrroline-5-carboxylate
(P5C), a proline-derived metabolite generated by proline oxidase,
inhibited the proliferation and survival of ECV-304 and DECV cells
and induced apoptosis in both cell lines. A recombinant proline
oxidase protein tagged with a green fluorescent protein at the
amino terminus localized to mitochondria and induced apoptosis in
p53-null H1299 non-small cell lung carcinoma cells. The results
directly implicate proline oxidase and the prolineyP5C pathway in
p53-induced growth suppression and apoptosis.
The p53 tumor suppressor protein plays multiple roles in cellcycle control (1–3), differentiation (4), genomic stability (5,
6), angiogenesis (7, 8), and apoptosis (9–13). After damage to
DNA, p53 is induced and activated to generate a late G1 block,
thus allowing DNA repair to proceed with fidelity (5, 6, 14–16).
Mutations that inactivate the p53 gene product are frequently
found in human cancers (17, 18), which has generated a concept
that p53 mutations impair cell cycle control, allowing further
mutations to accumulate increasing the risk for cancer. The p53
protein functions as a sequence-specific DNA-binding factor and
can activate genes whose promoters contain a p53 response
element (reviewed in refs. 19 and 20). Genes involved in the
regulation of the cell cycle, apoptosis, and DNA repair are
transactivated by p53 (19–21).
To identify other genes involved in p53-mediated apoptosis of
transformed cells, we selected for ECV-304 bladder carcinoma
cells that exhibited resistance to apoptosis induced by p53.
Proline oxidase, an enzyme involved in the prolineypyrroline-
5-carboxylate (prolineyP5C) redox pathway, was identified as a
p53-induced gene in ECV-304 tumor cells. Both P5C and a
recombinant proline oxidase protein exhibited the ability to
inhibit cell growth and to induce apoptosis, suggesting that the
proline oxidase pathway may play a role in p53-mediated growth
inhibition and apoptosis.
Materials and Methods
Cell Lines and Cell Culture. Recent investigation by the American
Type Culture Collection using DNA profiling has revealed that
the ECV-304 cell line is genetically similar to the T24 bladder
carcinoma cell line (see http:yywww.atcc.org). The DECV cell
line was generated from ECV-304 by selection for resistance to
p53-mediated apoptosis (22). ECV-304 and DECV cells were
maintained and propagated in DMEM containing 10% FCS.
Construction of a Recombinant Green Fluorescent Proline Oxidase
Expression Vector. Attempts to clone the complete proline oxidase
cDNA proved unsuccessful, potentially because of complex
DNA structure at the 59 portion of the cDNA or the mRNA used
to generate cDNA. However, cDNA encoding amino acids
186–516 of proline oxidaseydehydrogenase I was obtained by
reverse transcription–PCR (RT-PCR) and cloned in the frame
of the pEGFP-C2 (CLONTECH) green fluorescent protein
(GFP) fusion expression vector.
Recombinant Adenoviruses. The construction and generation of
Ad5CMV-p53 and Ad5CMV-galactosidase have been described
(23). The GFP recombinant adenovirus was constructed by
using the pAdTrack vector, which contains GFP, and gener-
ating recombinant adenoviruses using the pAdeasy-1 vector as
described (24).
Generation of ECV-304 Cells Resistant to p53-Mediated Apoptosis.
ECV-304 cells resistant to p53-mediated apoptosis were gener-
ated by repeated infections with Ad5CMV-p53 as described (22).
The details of the cell behavior differences between DECVs and
the parental ECV-304 cells are reported elsewhere (22).
RNA Preparation and Analysis. For RT-PCR and Northern analy-
ses, total cellular RNA was extracted with TRI-REAGENT
(Molecular Research Center, Cincinnati) according to the sug-
gested manufacturer’s protocol. RNA was harvested at 12 h after
infection with recombinant p53 adenovirus when signs of apo-
ptosis were minimally visible in the ECV-304 cells. After analysis
of quality by formaldehyde agarose gel electrophoresis, the total
RNA was then used in RT-PCR assays or extracted further to
isolate poly(A)1RNA.
DNA Microarray Analysis. To isolate poly(A)1RNA to generate
fluorescent DNA probes in DNA microarray hybridization, total
RNA isolated with TRI-REAGENT was extracted four times
with phenol-chloroform, ethanol-precipitated, and resuspended
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in diethyl pyrocarbonate-treated water to give a final concen-
tration of 0.5 mgyml. Contaminating DNA was removed by
incubating the RNA mixture with DNase I (50 unitsy0.5 mg
RNA) at 37°C for 1 h. The reaction was terminated by adding 100
ml of 0.1 M EDTA (pH 8.0), and the RNA was extracted twice
with phenol-chloroform. The RNA was ethanol-precipitated,
washed once with 80% ethanol, and resuspended in 2 ml of
diethyl pyrocarbonate-treated water. Poly(A)1RNA was iso-
lated from the total RNA, using Oligotex resin in a batchwise
protocol (Qiagen, Chatsworth, CA). The poly(A)1RNA from
p53-induced ECV-304 and p53-induced DECV cells was used to
generate carbocyanine 5- and carbocyanine 3-labeled cDNA,
respectively, for competitive hybridization of a DNA microarray
grid containing 5,730 sequences of known genes and expressed
sequence tags (UniGEM Human V screening services; Genome
Systems, St. Louis).
Northern Blotting. Total cellular RNA was isolated as described
above, run on a 1% agarose minigel (4 mg per gel lane)
containing 2.2 M formaldehyde, and transferred to a nitrocel-
lulose membrane (Schleicher & Schuell). Membranes were dried
at room temperature, and RNA was cross-linked by UV irradi-
ation in a Stratalinker (Stratagene). Hybridization was per-
formed in ExpressHyb hybridization buffer (CLONTECH) con-
taining 1 3 106 cpmyml of 32P-labeled cDNA probe at 65°C for
24 h. Blots were washed at 65°C for 15 min in 13 SSC (0.15 M
sodium chloridey0.015 M sodium citrate, pH 7) and 0.1% SDS
followed by a wash in 0.13 SSC and 0.1% SDS for 15 min.
RT-PCR. Total RNA was extracted as described above, and cDNA
was synthesized according to the Advantage RT-for-PCR pro-
cedure (CLONTECH). The primers for PCR were used at an
excess concentration of 500 ng in a 50-ml final reaction volume.
PCR was performed by using AmpliTaq DNA polymerase under
conditions described in the CLONTECH Advantage RT-for-
PCR kit (94°C for 45 s; 60°C for 45 s; 72°C for 2 min; 25 cycles;
7 min final extension at 72°C). The PCR were performed in the
linear range of the reaction to obtain a semiquantitative result.
The products generated in each PCR were cloned into the TA
cloning vector system (Invitrogen) and sequenced to confirm the
appropriate identity of the cDNAs.
Flow Cytometry [Fluorescence-Activated Cell Sorter (FACS)]. The
green fluorescent apoptotic cells expressing GFP or GFP-
proline oxidase were quantified as the proportion of cells that
contained a DNA content of less than 2 M (subG1 DNA
content), as described for analysis of p53-mediated apoptosis
(22, 25). H1299 cell monolayers (3–5 3 106 total cells) were
trypsinized, washed twice in PBS at 4°C, and fixed in 70%
ethanol as described (22).
Cell Proliferation Assays. Cells (1 3 105) were seeded into wells of
a 24-well culture plate and incubated with or without recombi-
nant adenoviruses or amino acids for the times indicated. WST-1
cell proliferation reagent (Roche Molecular Biochemicals) was
added directly to the supernatant (10 mly200 ml growth medium),
and the cell cultures were returned to the incubator for 1–2 h.
The absorbency of the formazan product was then determined
at 460 nm.
Isolation of Mitochondria. Mitochondria were isolated by centrif-
ugation through a sucrose cushion as described (26). The mito-
chondrial pellet was washed twice in hypertonic lysis buffer and
suspended in 200 ml of the same buffer, and 2 ml was solubilized
in SDS gel loading buffer for analysis of GFP-proline oxidase by
immunoblotting.
Confocal Microscopy. H1299 cells were transfected for 24 h with
GFP-proline oxidase, typsinized as described above, and re-
seeded onto glass coverslips precoated with collagen. After 24 h,
medium was removed and the cell monolayers on the coverslips
were rinsed once with basal DMEM lacking FCS. The coverslips
were rinsed once in basal medium and overlaid with basal
medium containing 300 nM MitoTracker Red mitochondrial
stain (Molecular Probes). The cells on the coverslips were then
incubated at 37°C for 30 min, mounted on glass slides, and sealed
with fingernail polish, and the excited green GFP-proline oxi-
dase and red MitoTracker fluorescence were viewed under a
Zeiss Ultima Z confocal f luorescence microscope.
Results
Generation of a p53-Resistant Derivative of ECV-304 Cells. ECV-304
cells express low levels of wild-type p53 and, when induced to
express high levels of the p53 protein by adenovirus-mediated
gene transfer, undergo extensive apoptosis, resulting in the
eventual death of almost all of the cells within 36 h (27). We
generated a derivative line of ECV-304 cells that is resistant to
p53-mediated apoptosis (differentiated ECVs or DECVs) as a
strategy to study the relevant molecular events in the apoptosis
of these transformed cells. The DECV cells were generated by
repeated selection of ECV-304 cells that were resistant to
apoptosis induced by the Ad5CMV-p53 adenovirus (22). The
parental ECV-304 cells but not DECV cells undergo extensive
apoptosis after infection with p53 recombinant adenovirus. The
same amount of p53 protein can be induced by adenovirus
infection in the DECV and ECV-304 cell lines, but apoptotic
death only occurs in a significant amount in the parental
ECV-304 cells. Immunofluorescent localization experiments
revealed a similar intracellular distribution of p53 in the two cell
lines, with a predominance of p53 observed in the nucleus (22).
Molecular Characterization of p53-Induced DECV and ECV-304 Cells. In
an initial attempt to identify the molecular basis for the resis-
tance of DECV cells to p53-mediated apoptosis, the expression
of apoptosis-associated genes was examined by semiquantitative
RT-PCR in ECV-304 and DECV cells up-regulated for wild-type
p53, by infection with Ad5CMV-p53. No differences in the
expression of Bcl-2, Bak, Bad, Waf-1, and Bax-a genes were
observed between DECV and ECV-304 cells up-regulated for
p53 (data not shown). The absence of any significant changes in
apoptotic gene expression between DECV and ECV-304 cells
prompted us to perform a DNA microarray analysis that in-
cluded sequences of a total of 5,730 known genes and expressed
sequence tag sequences. RNA was harvested at 12 h after
infection with recombinant adenovirus, a time when signs of
apoptosis are minimally visible in the ECV-304 cells, and used
to generated carbocyanine 3- and carbocyanine 5-labeled cDNA
for competitive hybridization on a DNA microarray grid. Apo-
ptosis occurs rapidly thereafter in ECV-304 cells, with as many
as 30–40% of the cells in apoptosis after 16–20 h of p53
up-regulation. Approximately 8% of the 5,730 genes examined
by DNA microarray analysis exhibited 2-fold or greater changes
in expression between p53-infected DECV and ECV-304 cells.
Table 1 is a partial list of genes that were detected to be
differentially expressed between p53-induced ECV-304 and
DECV.
RT-PCR was performed to confirm the differential expression
of some of the genes identified by DNA microarray. Analysis of
glyceraldehyde 3-phosphate dehydrogenase and Bad transcript
levels, which show no changes in expression in p53-infected
ECV-304 and DECV cells, were used as controls to ensure that
equivalent amounts of cDNA were included in each assay (Fig.
1). In all cases, p53 either repressed or induced differentially the
expression of the genes that were analyzed (Fig. 1). Cyclin A1,
Pig-11, Baxd, BTG2, Pig-3, and Apaf-1 were observed to be
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induced more highly by p53 in ECV-304 cells than in DECV
cells, whereas XRCC9, PISSLRE, and E2F were repressed by p53
in ECV-304 cells to greater degrees than in DECV cells. The
Bcl-2, Bak, and Bcl-XL anti-apoptotic genes were dramatically
repressed by p53 in both ECV-304 and DECV cells. The patterns
of expression of these genes are specific, inasmuch as no changes
in the expression of glyceraldehyde 3-phosphate dehydrogenase
or Bad occurred in response to induction of p53. Northern
blotting for expression of cyclin A1 generated results similar to
the microarray and RT-PCR data by showing a much greater
induction of cyclin A1 by p53 in ECV-304 cells than in DECV
cells (data not shown) and thus validated the results of the DNA
microarray and RT-PCR analyses. The induction of arginase II,
proline oxidase, and cyclin A1 was specific to the up-regulation
of p53, inasmuch as no increases in expression of those genes
were detected by RT-PCR in control GFP adenovirus-infected
cells or cells treated with P5C (Fig. 2 B–D).
Up-Regulation of Enzymes Involved in the ProlineyP5C Redox Cycle in
p53-Induced Cells. Two enzymes involved in a redox pathway were
observed to be up-regulated more than 5-fold by DNA microar-
ray analysis in p53-induced ECV-304 cells than in p53-induced
DECV cells (Table 1). Proline oxidase, a mitochondrial enzyme,
is involved in the transfer of redox potential across the mito-
chondrial membrane through the prolineydelta-P5C (proline-
P5C) pathway (28). Proline oxidase has also been previously
identified as a p53-induced gene (PIG6) in a colorectal cell line
(29). Arginase II, a cytoplasmic and mitochondrial enzyme, may
Fig. 1. Differential regulation of gene expression by p53 in ECV-304 and
DECV cells. ECV-304 and DECV cells were infected with control recombinant
b-galactosidase adenovirus (ECVygal; DECVygal) or recombinant p53 adeno-
virus (ECVyp53; DECVyp53) for 12 h. Total RNA was extracted and subjected to
RT-PCR to analyze the expression of XRCC9, Bcl-2, PISSLRE, BTG2, Apaf-1, Bax,
Pig-3, Pig-11, BclXL, E2F, Bak, protocadherin-42 (PRCAD-42), cyclin A1 (CYCLIN
A), and HLH 1R21 (HLHP). Glyceraldehyde 3-phosphate dehydrogenase and
Bad, which were not influenced by p53, were used as expression controls to
ensure that equivalent amounts of cDNA were included in each assay.
Fig. 2. Induction of proline oxidase and arginase II in ECV-304 cells up-
regulated for p53. (A–D) RT-PCR was performed to analyze p53 (A), arginase
II (B), proline oxidase (C), and cyclin A1 (D) in mock-infected (lane 1), GFP
recombinant adenovirus-infected (lane 2), p53 recombinant adenovirus-
infected (lane 3), DMSO-treated (lane 4), and P5C-treated (lane 5) ECV-304
cells. (E) Northern blot analysis was performed on total RNA isolated from
mock-infected (lane 1), GFP-infected (lane 2), and p53-infected (lane 3) ECV-
304 cells using a radiolabeled proline oxidase cDNA probe and shows induc-
tion of proline oxidase mRNA only in p53-induced cells. (F) After capillary
transfer from the agarose gel to a nylon membrane, total RNA was stained
with methylene blue before hybridization with the proline oxidase probe and
shows equivalent amounts of quality total RNA in each gel lane.




Cyclin A1 Associates with cdk2 protein kinase at S and G2-M phases (39) 6.5
PISSLRE CDC2-related protein kinase essential for cell proliferation and acts at G2-M phase (40) 22.0
HLH 1R21 Inhibitor of DNA binding (41), member of Id helix–loop–helix family of negative regulators of
differentiation
4.6
Protocadherin-42 Cell–cell adhesion and communication (42) 28.0
Apaf-1 Activates caspase-9 (43) 2.9
XRCC9 DNA postreplication repair or cell cycle checkpoint control (44) 22.1
E2F Positive regulator for entry into S phase (45) 23.2
BTG2 Involved in p53-dependent cell cycle control and the cellular response to DNA damage (46) 2.4
PIG-3 p53-induced apoptosis-associated gene (29) 2.5
PIG-11 p53-induced apoptosis-associated gene (29) 3.6
*A positive number indicates that a gene was expressed at higher levels in ECV-304 cells than in DECV, and a negative value indicates higher expression in DECV.








be connected to the proline-P5C pathway by converting arginine
to ornithine, which can be used by ornithine aminotransferase to
produce P5C (30). RT-PCR confirmed that proline oxidase and
arginase II were induced specifically in cells up-regulated for p53
but not in mock-infected cells or in cells infected with GFP
control adenovirus (Fig. 2 B and C, respectively). The two
enzymes were also confirmed by RT-PCR to be differentially
expressed in ECV-304 and DECV cells up-regulated for p53
(data not shown). Northern blotting also showed induction of
proline oxidase in p53-induced cells but not in GFP-infected or
mock-infected cells (Fig. 2E).
Proline oxidase catalyzes the conversion of proline to P5C,
which has been reported to function as a metabolic signal
regulated by humoral factors to coordinate the metabolism of
amino acids and ribonucleotides (28). Both proline and P5C have
been shown to be transferred from cell to cell and function as
intercellular communicators through the transfer of oxidizing
and reducing potential. We thus were interested in determining
the effect of P5C on cell growth and whether it was capable of
inducing apoptosis. P5C was purchased commercially as a dini-
trophenylhydrazone conjugate, which was solubilized in DMSO
and added directly to the cell culture media. Dinitrophenylhy-
drazine by itself produced little or no toxicity in any of the cell
types that we investigated, at concentrations as high as 800 mM
and for the time duration used in this study (data not shown).
P5C that was acid-extracted and purified from the 2,4-
dinitrophenylhydrazine (DNP) was found not to be as efficient
in entering cells as the dinitrophenylhydrazone conjugate (DNP-
P5C) and exhibited much less of an effect on cell growth than the
DNP-P5C compound. We believe that the DNP moiety facili-
tated the entry of P5C into cells.
The effect of the DMSO-solubilized DNP-P5C compound on the
growth of several transformed and normal cells was investigated.
DNP-P5C was observed to inhibit the proliferation and survival of
DECV and ECV-304 cells (Fig. 3C). The growth of H358 non-small
cell lung carcinoma, human umbilical vein endothelial cells, and
normal fibroblast cells was also inhibited by DNP-P5C (data not
shown). The inhibitory effect was maximal at doses of 400 mM for
most of the different cell types, with human umbilical vein endo-
thelial cells being the most sensitive. Several amino acids showed no
effect on cell number at doses similar to and much higher than that
of P5C (data not shown), indicating that the inhibition of growth
was specific for the P5C metabolite.
Flow cytometry (FACS) was used to determine whether P5C
influenced apoptosis in ECV-304 cells. Apoptotic cells were quan-
tified as the proportion of cells that had a DNA content of less than
2 N (sub-G1 DNA content), as previously described for analysis of
cells undergoing p53-mediated apoptosis (22, 25). FACS scan
analysis and internucleosomal fragmentation assays indicated that
22% of the ECV-304 cell population was undergoing apoptosis
after 48 h of treatment with DNP-P5C (Fig. 3B). In contrast,
approximately 1% of the ECV-304 cells were undergoing apoptosis
with the added DMSO vehicle control (Fig. 3A). Internucleosomal
DNA fragmentation analysis confirmed the detection of apoptosis
in the FACS analysis by revealing the characteristic DNA ladder in
DNP-P5C-treated ECV-304 and DECV cells, along with a consid-
erable amount of a DNA smear (Fig. 3D).
To determine whether proline oxidase could directly mediate
apoptosis in the absence of p53, H1299 cells devoid of endog-
enous p53 were transiently transfected with a recombinant
hybrid protein containing GFP fused to amino acids 186–516 of
proline oxidase. Expression of GFP and the GFP-proline oxidase
proteins is shown in Fig. 4A. H1299 cells transiently transfected
with the GFP-proline oxidase expression vector underwent
significantly higher rates of apoptosis than cells expressing only
GFP (Fig. 4 B and C). Levels of apoptosis in GFP-proline
oxidase-expressing cells were not as high as those in cells
up-regulated for p53 (Fig. 4C). Subcellular fractionation re-
vealed that GFP-proline oxidase localized predominantly in the
Fig. 3. P5C inhibits growth and induces apoptosis in p53-sensitive and
p53-resistant cells. (A and B) FACS was performed on ECV-304 cells treated
with DMSO (A) and on cells treated with P5C (B) for 16 h. (C) P5C inhibited the
proliferation and reduced the survival of DECV and ECV-304 cells. (D) Inter-
nucleosomal DNA fragmentation analysis supported the FACS analysis in
showing DNA fragmentation ladders characteristic of apoptosis. DMSO-
treated ECV-304 and DECV are shown in lanes 1 and 2, and ECV-304 and DECV
cells treated with 600 mM P5C for 36 h are shown in lanes 3 and 4, respectively.
Fig. 4. A recombinant GFP-proline oxidase induces apoptosis in H1299
non-small cell lung carcinoma cells. (A) H1299 cells were transfected with GFP
(lane 1) or GFP-proline oxidase (lane 2) expression vector for 24 h and immu-
noblotted with a polyclonal GFP antibody. (B) H1299 cells at 40–50% conflu-
ence were transfected with GFP or GFP-proline oxidase and subjected to FACS
analyses 72 h later. (C) Quantitation of apoptosis occurring in cells transfected
with GFP, GFP-proline oxidase fusion protein, or a combination of GFP 1 p53.
The data values shown were compiled from four independent FACS scans.
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mitochondria (Fig. 5A, lane M), with only trace amounts found
in the nuclear (Fig. 5A, lane N) and cytoplasmic (Fig. 5A, lane
C) compartments. Cytochrome c, a mitochondrial marker, con-
firmed that mitochondria had been purified, because it was
found most predominantly in the mitochondrial fraction (Fig.
5B, lane M). Confocal microscopy confirmed the subcellular
fractionation results by showing the colocalization of GFP-
proline oxidase with mitochondria, which were concentrated at
perinuclear areas in the cytoplasm of H1299 cells (Fig. 5C).
MitoTracker Red was used to localize mitochondria, and the
colocalization of the excitated green GFP-proline oxidase with
MitoTracker Red resulted in a yellow color in the confocal
imaging (Fig. 5C, Colocalization). We conclude that a proline
oxidase molecule localizes to the mitochondria and is capable of
inducing apoptosis in a transformed human cell line.
Discussion
We have shown that induction of wild-type p53 by adenovirus-
mediated gene transfer leads to rapid and extensive apoptosis in
ECV-304 cells (27). To identify molecular events relevant to
p53-mediated apoptosis in ECV-304 cells, we established a
variant of ECV-304 (DECV) that is resistant to p53-mediated
apoptosis. The DECV cells appear to represent a more differ-
entiated, less tumorigenic variant of ECV-304 cells, based on the
formation of lattice- and cyst-like structures in culture, the lower
efficiency of growth in soft agar, and the demonstration of
contact inhibition (22).
Serial analysis of gene expression in a p53-induced colorectal
cell line identified several p53-regulated genes involved in
control over the redox status of cells (29). Two of those redox
regulators, PIG3 (quinone oxidoreductase homolog) and PIG6
(proline oxidase), were also up-regulated by p53 in the sensitive
ECV-304 but not in the resistant DECV cells. We identified
several other redox regulators that were differentially expressed
in p53-sensitive and p53-resistant endothelial cells. These in-
cluded arginase II, g-glutamyl transferase-2, and NADH ubiqui-
none dehydrogenase Fe-S protein-5. The differential induction
of proline oxidase by p53 between ECV-304 and DECV cells and
the ability of a recombinant proline oxidase protein to induce
apoptosis are observations that are of particular interest, be-
cause this enzyme is involved in the transfer of reducing equiv-
alents between the cytoplasm and mitochondria. Proline oxidase
catalyzes the conversion of proline to P5C and transfers elec-
trons into the mitochondrial electron transport with an inter-
vening flavoprotein (31). These interconversions have been
postulated to shuttle redox between cellular compartments,
transfer electrons from NADPH to NAD1, couple the oxidation
of NADPH to mitochondrial electron transport, and serve as a
mechanism for energy production (28). The conversion of P5C
to proline ultimately leads to stimulation of the oxidation of
glucose through the pentose phosphate pathway, resulting in the
production of ribose 5-phosphate. Increases in ribose 5-phos-
phate lead to increases in phosphoribosylpyrophosphate, a crit-
ical intermediate for nucleotide synthesis (28). An increase in the
concentrations of nucleotide pools is thus implicated as one
outcome of the induction of the prolineyP5C pathway by p53,
and this increase might influence gene expression and activities
of caspases. For instance, nucleotide pools have been shown to
be important in influencing gene expression in HL60 promyelo-
cytic leukemia cells (32), and a p53-inducible ribonucleotide
reductase is required to mediate efficient repair of damaged
DNA (21). Moreover, cellular nucleotide pools have been im-
plicated in a reversible p53-dependent G0yG1 cell cycle arrest
(33) and in the role of dATP in the activation of caspase-induced
apoptosis (34). Finally, ATP appears to be required for down-
stream events in apoptosis (35).
Mitochondria participate in apoptosis by activating caspases
through the release of cytochrome c into the cytosol, where it
binds to Apaf-1 and activates caspase pathways (34, 36). It is thus
intriguing that ferricytochrome c is a required cofactor in the
conversion of proline to P5C by proline oxidase in vitro (37).
Moreover, caspases are cysteine-dependent enzymes and appear
to be redox sensitive (38). A truncated recombinant proline
oxidase protein was still capable of localizing to mitochondria
and inducing apoptosis in H1299 cells. The shuttling of redox
potential from the mitochondria to the cytoplasm through the
prolineyP5C pathway might influence caspase activity. However,
we acknowledge that proline oxidase may mediate apoptosis
through pathways other than the P5C metabolite.
The differential sensitivity of ECV-304 cells and DECV cells to
p53 provides a model system for identifying molecular events
important in the p53-mediated apoptosis of tumor cells. Using this
system, we have identified several potential targets of p53 that may
play roles in growth suppression or apoptosis or both. All but one
(protocadherin-42) of the genes identified to be differentially
expressed between p53-induced ECV-304 and DECV cells were
found to be regulated by p53, indicating that this system will allow
for the identification of other genes regulated by p53. The com-
plexity of differential gene expression regulated by p53 identified by
DNA microarray in our system indicates that a diverse array of
genes may potentially play synergistic or additive roles in p53-
mediated apoptosis in vitro and in vivo.
This work was supported by a grant (1-RO1-HL59373) from the National
Heart, Lung, and Blood Institute.
Fig. 5. Recombinant GFP-proline oxidase localizes to mitochondria. Cells
were subfractionated into nuclei (N), cytoplasmicymembrane (C), and mito-
chondrial (M) fractions. (A and B) A portion of each subcellular fraction (5 mg
protein) was solubilized in SDS gel loading buffer and immunoblotted with a
polyclonal GFP antibody (A) or a monoclonal cytochrome c antibody (B). (C)
Confocal microscopy was used to visualize the localization of GFP-proline
oxidase in transfected H1299 cells (GFP-POX; green fluorescence). These same
cells were counterstained with MitoTracker Red (red fluorescence) to visualize
the localized concentration of mitochondria in the cytoplasm. The right panel
shows the simultaneous excitation of GFP-proline oxidase and MitoTracker
Red in the same field as that shown in the left and middle panels, which
yielded a yellowish-red fluorescence at areas of colocalization of GFP-POX and
MitoTracker Red. Filtered control analyses indicated that there was no con-
tamination of the red fluorescence window by the green fluorescence signal
or of the green fluorescence window by the red fluorescence signal.
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